You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Diabetes Articles
Popular Diabetes Articles
Highly Recommended Diabetes Articles
Send a link to this page to your friends and colleagues.
It's a fact that Byetta reduces A1c's, post-meal and fasting glucose levels, and weight in people with type 2 diabetes. The drawback is that it's another injection twice a day. In response, Amylin, the maker of Byetta, has developed exenatide LAR, a form of Byetta that is injected only once a week.
A phase 2 clinical trial recently published in Diabetes Care has found that like Byetta, exenatide LAR improves blood glucose control and causes weight loss in people with type 2 diabetes. In the placebo-controlled study, exenatide LAR was given subcutaneously once weekly for 15 weeks to 45 patients with type 2 diabetes. At the outset, they were not well controlled on metformin or with diet and exercise, and their average A1c was 8.5 percent. Each patient on exenatide LAR received either 0.8 or 2.0 mg.
Both doses of the LAR formula reduced fasting plasma glucose and average daily blood glucose, both of which increased in the placebo group. A1c's increased slightly in the placebo group but decreased in the exenatide LAR patients, by 1.4 points in the 0.8 mg group and by 1.7 points in the 2.0 mg. group. The 2.0 mg LAR group lost an average of 8.4 pounds, but the 0.8 mg group and the placebo group lost no weight. No one had to discontinue the treatment due to adverse events.
Source: Diabetes Care 2007
Jul 13, 2007
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.